NorthWest Biotherapeutics Inc (NWBO)

[MI Dendream]

Intellia has one gene editing therapy in humans. They also have a pieline, but are using an inferior technology. Yet, one dose in one human jumped them to $5B MC, and short term safety reported in 3 patients propelled them to $12B. Gene editing has great promise. It also has great competition and anyone using CRISPR/TALEN has limitations on which genetic diseases are in play.

This company is on the verge of an instant $5B in revenue for GBM practically overnight. This alone deserves a $20B MC upon approval. Factor in pipeline and you should see the market go absolutely bananas over DCVax.

Moderna’s $7B in revenue commands $66B MC and because of the promise of their pipeline once reached $150B. They have a good pipeline, ours is substantially better. No one paid attention before COVID.

If you follow how biotech’s spike before landing in reality of the moment, they usually go about 3x higher, that means NWBO has the potential to make me and my cabal able to make a big, big move into a company next time. A $66B MC is about $56 per share fully diluted to the shelf.

When they expand into sarcoma and colon cancer, it could go Tesla big. That is not crazy talk. Linda may decide to buy any other assets she wants and even BP may not be able to compete for bidding.

Hard to believe, but possible in the short term.

This is why the shorts are crapping their pants.